Clinical trials: Anticoagulant Therapy, open to volunteers
Portal Vein Thrombosis, Anticoagulant Therapy
Direct Oral Novel Anticoagulants for Patients With High-risk Gastroesophageal Variceal Bleeding and Portal Vein Thrombosis
This study aims to explore the safety and efficacy of oral administration of a novel anticoagulant (rivaroxaban) in patients with cirrhosis accompanied by high-risk esophagogastric variceal bleeding and portal vein thrombosis…
- Conditions
- Portal Vein Thrombosis, Anticoagulant Therapy, Variceal Bleeding
- Trial name
- NCT07602062
- Testing
- Rivaroxaban
- Where
- China
- Volunteers
- 175 people
- Sponsor
- Shanghai Zhongshan Hospital
Fibrillation, Atrial
Thromboembolic And Bleeding Risks During anticoaGulant trEatment in Asian paTients With Atrial Fibrillation (TARGET-AF)
This study was design to investigate the efficacy and safety of NOAC therapy in Koreans
- Trial name
- NOAC (NCT06874894)
- Where
- 2 sites in South Korea
- Volunteers
- 1,021 people
- Sponsor
- Chung-Ang University Hospital
Venous Thromboembolism, Active Cancer
Edoxaban Versus Apixaban in Cancer-Associated Venous Thromboembolism
This prospective, multicenter, randomized, open-label, blinded-endpoint trial aims to compare the clinical efficacy and safety of edoxaban-based treatment versus apixaban-based treatment in patients with cancer-associated venous…
- Trial name
- NEXT-CAT (NCT07852637)
- Testing
- edoxaban, Apixaban
- Where
- 12 sites in South Korea
- Volunteers
- 2,300 people
- Sponsor
- Samsung Medical Center
Pregnancy, Prosthetic Heart Valve
Optimizing Anticoagulation in Pregnancies With Mechanical Heart Valves
The purpose of this pilot study is to collect data on pregnancies with mechanical heart valves to see if using a blood thinner called low molecular weight heparin (LMWH) and low dose aspirin (LDA) is comparable to…
- Conditions
- Pregnancy, Prosthetic Heart Valve, Anticoagulant Therapy
- Trial name
- NCT07658989
- Testing
- LMWH and LDA, Vitamin K antagonists (e.g warfarin)+/- LDA, Sequential therapy +/- LDA
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- Mount Sinai Hospital, Canada
Benign Prostatic Hyperplasia, Postoperative Hemorrhage
Perioperative Dutasteride for Hemorrhage Control in Bipolar TURP Under Anticoagulation.
A prospective, randomized, double-blinded controlled trial to evaluate the efficacy of a 2-week preoperative and 2-week postoperative course of oral dutasteride (0.5 mg daily) in reducing perioperative blood loss, irrigation…
- Conditions
- Benign Prostatic Hyperplasia, Postoperative Hemorrhage, Perioperative Hemorrhage Control During Bipolar Transurethral Resection of the Prostate (TURP) in Patients on Anticoagulant or Antiplatelet Therapy
- Trial name
- DUT-TURP (NCT07911501)
- Testing
- Dutasteride (0.5mg)
- Where
- Egypt
- Volunteers
- 44 people
- Sponsor
- Mohamed Mahmoud Dogha
Antithrombinemia
Evaluation of the Relevance of Antithrombin Prescriptions at Strasbourg University Hospitals
Antithrombin (AT) is a physiological inhibitor of the coagulation cascade. In therapeutics, its presence in sufficient quantities is necessary for the pharmacological activity of unfractionated heparin (UFH) and partially…
- Trial name
- EPPATHUS (NCT07276074)
- Where
- France
- Volunteers
- 160 people
- Sponsor
- University Hospital, Strasbourg, France
Ischemic Stroke
Safety and Efficacy of Intravenous Thrombolysis in Patients With Ischemic Stroke and Direct Oral Anticoagulants Intake
DO-IT is an international, multicenter, prospective, two-arm, randomized, open label, blinded endpoint superiority trial determining the safety and efficacy of intravenous thrombolysis (IVT) in participants experiencing an acute…
- Trial name
- DO-IT (NCT06571149)
- Testing
- Tenecteplase or Alteplase
- Where
- 109 sites in Austria, Belgium and 10 more
- Volunteers
- 906 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Atrial Fibrillation, Venous Thromboembolism
START-Register: Survey on Anticoagulated Patients Register
This is a phase 4 cohort prospective, open, national, multicentre study that collects data on history of patients treated chronically with anticoagulant drugs, including the novel direct oral anticoagulants (DOACs).
- Conditions
- Atrial Fibrillation, Venous Thromboembolism, Heart Valve Diseases or Prosthesis
- Trial name
- NCT02219984
- Testing
- Anticoagulants
- Where
- Italy
- Volunteers
- 15,410 people
- Sponsor
- GUALTIERO PALARETI
Atrial Fibrillation, Atrial Appendage
AntiPlatelet theraPy stratEgy followiNg Left Atrial appenDAGe closurE
The APPENDAGE study is a phase 4 multicentre randomized opened clinical trial comparing 2 different antithrombotic strategies following left atrial appendage closure (LAAC) in patients with non valvular atrial fibrillation (AF).
- Conditions
- Atrial Fibrillation, Atrial Appendage, Anticoagulants, Stroke
- Trial name
- APPENDAGE (NCT04796714)
- Testing
- Double antiplatelet therapy, Aspirin, Brain MRI
- Where
- 2 sites in France
- Volunteers
- 60 people
- Sponsor
- University Hospital, Bordeaux
Hemorrhage, Thrombosis
Adverse Drug Events in Patients on Oral Anticoagulation in the Emergency Department
Rationale: According to the latest National Survey on Care-Related Adverse Events, anticoagulants, including vitamin K antagonists (VKAs), rank first among medications responsible for serious iatrogenic accidents (37% in 2004…
- Conditions
- Hemorrhage, Thrombosis, Anticoagulant Therapy, Traumatic Hemorrhage
- Trial name
- ADEOA (NCT06692504)
- Where
- France
- Volunteers
- 2,080 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Coronary Artery Disease, Percutaneous Coronary Intervention
Potassium-Competitive Acid Blocker Versus pROton-Pump Inhibitor for GastroproTECTion Strategies In Patients at High Gastro-Intestinal Bleeding Risk Receiving Antithrombotic Therapy
The primary aim of this study is to evaluate the efficacy and safety of novel P-CAB (tegoprazan 50 mg once daily) as compared with standard PPI (rabeprazole 20 mg once daily) for protection of GI events in patients with known…
- Conditions
- Coronary Artery Disease, Percutaneous Coronary Intervention, Acute Coronary Syndrome, Myocardial Infarction
- Trial name
- PROTECT-HBR (NCT04416581)
- Testing
- PPI, P-CAB 50
- Where
- 45 sites in South Korea
- Volunteers
- 3,320 people
- Sponsor
- Duk-Woo Park, MD
Stroke, Stroke (in Patients With Atrial Fibrillation)
Thrombolysis in Factor Xa-inhibitors Trial
This study looks at whether stroke patients who take FXa inhibitors (a type of blood thinner) can safely receive clot-busting treatment (IVT).
- Conditions
- Stroke, Stroke (in Patients With Atrial Fibrillation), Ischemic Stroke, Acute Ischemic Stroke
- Trial name
- SIFT (NCT06878066)
- Testing
- thrombolysis therapy
- Where
- 21 sites in Denmark, Norway and 1 more
- Volunteers
- 300 people
- Sponsor
- Guri Hagberg
Cerebral Venous Thrombosis
Treatment Outcomes of Direct Oral Anticoagulants in Cerebral Venous Thrombosis in Vietnam
This prospective, single-arm observational cohort study aims to evaluate the real-world effectiveness and safety of direct oral anticoagulants (DOACs), specifically dabigatran or rivaroxaban, in patients with cerebral venous…
- Trial name
- DCVT-VN25 (NCT07083609)
- Testing
- Dabigatran, Rivaroxaban
- Where
- Vietnam
- Volunteers
- 69 people
- Sponsor
- Hieu Trung Dinh
Hereditary Hemorrhagic Telangiectasia, Rendu Osler Disease
Prospective Study of Antiplatelet and Anticoagulation Therapy in Hereditary Haemorrhagic Telangiectasia
The goal of this clinical trial is to evaluate in real life, in patients with Hereditary Hemorrhagic Telangiectasia (HHT), the tolerance of the strategy of use of anticoagulant and/or antiplatelet, by comparing a new exposure…
- Trial name
- PROPLACO-Tel (NCT05641142)
- Testing
- monitoring the use of anticoagulant and/or antiplatelet therapy in patients with osler rendering disease
- Where
- 18 sites in France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Clermont-Ferrand
Medication Adherence, Atrial Fibrillation (AF)
SNAP AF-52: Dose Appropriateness and Adherence to Oral Anticoagulation in Adults ≥65 With Atrial Fibrillation in Primary Care (Ordu, Türkiye)
SNAP AF-52 is an ambidirectional observational registry conducted in family health centers (primary care) across Ordu, Türkiye, enrolling adults ≥65 years with a pre-existing diagnosis of atrial fibrillation.
- Conditions
- Medication Adherence, Atrial Fibrillation (AF), Direct Oral Anticoagulants (DOACs)
- Trial name
- SNAP AF-52 (NCT07242326)
- Where
- Turkey (Türkiye)
- Volunteers
- 1,000 people
- Sponsor
- Kotyora Family Medicine Health Management and Education Association
Acute Coronary Syndrome, Myocardial Infarction
What is the Optimal Antithrombotic Strategy in Patients With Atrial Fibrillation Undergoing PCI?
The optimal antithrombotic management in patients with coronary artery disease (CAD) and concomitant atrial fibrillation (AF) is unknown.
- Conditions
- Acute Coronary Syndrome, Myocardial Infarction, Atrial Fibrillation, Atrial Flutter
- Trial name
- WOEST-3 (NCT04436978)
- Testing
- 30-day DAPT, Guideline-directed therapy
- Where
- 20 sites in Belgium, Netherlands
- Volunteers
- 2,000 people
- Sponsor
- St. Antonius Hospital
Ischemic Stroke, Transient Ischemic Attack
Zastaprazan for the prEvention of Upper GI Bleeding in Ischemic Stroke
The goal of this clinical trial is to learn if zastaprazan can help prevent upper gastrointestinal bleeding in adults who have recently had a transient ischemic attack (TIA) or ischemic stroke and are taking antiplatelet or…
- Trial name
- NCT07730840
- Testing
- Zastaprazan
- Where
- 15 sites in South Korea
- Volunteers
- 984 people
- Sponsor
- Asan Medical Center
Antiphospholipid Syndrome, Thrombosis
International Registry of Thrombotic APS Patients Treated With Direct Oral Anticoagulants
This registry, currently being established will ensure consistency of data collection and provide safety information in non high-risk APS patients currently on DOACs.
- Conditions
- Antiphospholipid Syndrome, Thrombosis, Anticoagulants Causing Adverse Effects in Therapeutic Use
- Trial name
- OBSTINATE (NCT04262492)
- Testing
- Rivaroxaban
- Where
- France
- Volunteers
- 500 people
- Sponsor
- Stéphane Zuily
Behcet Disease, Behcet Disease and Vascular Involvement
Immunosuppressive Therapy Alone Versus Plus Oral Anticoagulation in the Treatment of VT Associated With Behcet's Disease
This study is a Phase III, multicenter, prospective, randomized, double-blind, placebo-controlled clinical trial investigating the treatment of lower extremity venous thrombosis associated with Behçet's Disease.
- Conditions
- Behcet Disease, Behcet Disease and Vascular Involvement, Deep Venous Thromboses, Post Thrombotic Syndrome
- Trial name
- BETTER (NCT06925698)
- Testing
- Rivaroxaban plus immunosupression
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 110 people
- Sponsor
- Marmara University
Atrial Fibrillation (AF), Atrial Fibrillation (Prevention of Stroke)
Stroke Risk Assessment and Markers of Blood Clotting in Patients With Newly Diagnosed Non-valvular Atrial Fibrillation (NVAF), Who Have Not Received Oral Anticoagulation Therapy (OAC-therapy) Prior to Inclusion
Background: Atrial fibrillation (AF) is the most common heart rhythm disorder worldwide. Globally, there are 37.5 million people with AF.
- Conditions
- Atrial Fibrillation (AF), Atrial Fibrillation (Prevention of Stroke), Atrial Fibrillation New Onset, Non Valvular Atrial Fibrillation
- Trial name
- BIO-AF (NCT06949319)
- Where
- Denmark
- Volunteers
- 150 people
- Sponsor
- Nedim Tojaga